Hey Grainger,
Amazing conversation you must have had, as other HC Members did at the AGM.
So clearly CYP have a very long road ahead (longer time frame than MSB + massive funding including reputational improvement to create the momentum for trial participation in USA) and it pleases me that potentially as MSB progress's commercially we may at a future point, buy CYP.
Great share!
Cheers
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-296
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.045(3.50%) |
Mkt cap ! $1.518B | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.35 | $1.30 | $2.885M | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 7070 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |